Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy

3 Jul 2024

Abstract excerpt

In general, ensuring safety is the top priority of a new modality. Although oncolytic virus armed with an immune stimulatory transgene (OVI) showed some promise, the strategic concept of simultaneously achieving maximum effectiveness and minimizing side effects has not been fully explored. We generated a variety of survivin-responsive "conditionally replicating adenoviruses that can target and treat cancer cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38969167
DOI: 10.1016/j.trsl.2024.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapyPMID 38969167Read ↗

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.Semantic proximity Read ↗

Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated VacciniaSemantic proximity Read ↗

Promoter choice: Who should drive the CAR in T cells?Semantic proximity Read ↗

Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic VirusesSemantic proximity Read ↗

Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating MoleculesSemantic proximity Read ↗

Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic AdenovirusesSemantic proximity Read ↗

Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenesSemantic proximity Read ↗

Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapySemantic proximity Read ↗

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene TherapySemantic proximity Read ↗

Designing adenoviral vectors for tumor-specific targeting.Semantic proximity Read ↗

Oncolytic Adenovirus Armed with cGAS Activates STING Pathway and Enhances Antitumor Immunity in Lung Cancer with Superior Combined Efficacy of PD-L1 TherapySemantic proximity Read ↗

Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible CytokinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.